Allogene Therapeutics Inc.

About Allogene Therapeutics Inc.

Allogene Therapeutics is dedicated to redefining the future of cell therapy by developing and delivering the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers, solid tumors, and autoimmune diseases. Their mission is to lead the next revolution in cell therapy with innovative, scalable, and accessible treatments.

Products & Services

AlloCAR T™ Product Platform:A pioneering platform for allogeneic CAR T cell therapies featuring multiplex gene-engineering, gene-editing capabilities, proprietary lymphodepletion, and state-of-the-art manufacturing.

Cemacabtagene Ansegedleucel (Cema-Cel):Frontline treatment for large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), currently in the ALPHA3 Phase 2 trial.

ALLO-316:Therapy for advanced renal cell carcinoma (ccRCC) with durable responses in heavily pretreated patients.

ALLO-329:Next-generation dual-targeted CD19/CD70 allogeneic CAR T therapy for autoimmune diseases like lupus, myositis, and scleroderma.

AlloCAR T cell therapies

Specialties

Allogeneic CAR T Cell Therapy Cell Therapy Innovation Gene Engineering and Editing Lymphodepletion Platforms Scalable Manufacturing Blood Cancers Solid Tumors Autoimmune Diseases Allogeneic CAR T cell therapy Cell therapy for blood cancers Cell therapy for solid tumors Cell therapy for autoimmune disease

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 200400000 MR: - FA: $200.4 million FAN: 200400000	D: 2026-04-16 FD: 2026-04-16	8 investors
2	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2026-04-14 FD: 2026-04-14	8 investors
3	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2026-04-13 FD: 2026-04-13	4 investors
4	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 110000000 MR: - FA: 110 million FAN: 110000000	D: 2024-05-13 FD: 2024-05-13	3 investors
5	RT: Grant T: - FT: Grant	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2024-04-26 FD: 2024-04-26	1 investors

Public Offering Latest

2026-04-16

$200.4M

8 investors (Pro only)

Public Offering 2026-04-14

$175.0M

Public Offering 2026-04-13

$175.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Arie Belldegrun, M.D.

Executive Chairman and Co-Founder

D

David Chang, M.D., Ph.D.

President, Chief Executive Officer and Co-Founder

B

Benjamin M. Beneski

Senior Vice President, Chief Technical Officer

C

Christine Cassiano

Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer

E

Earl Douglas

General Counsel

S

Susie Lundeen

Chief People Officer

View 20 more team members with Pro

Unlock Full Team Directory

Recent News